Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp.

Shigellosis (bacillary dysentery) is a severe gastrointestinal infection with a global incidence of 90 million cases annually. Despite the severity of this disease, there is currently no licensed vaccine against shigellosis. Shigella’s primary virulence factor is its type III secretion system (T3SS)...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ti Lu, Sayan Das, Debaki R. Howlader, Akshay Jain, Gang Hu, Zackary K. Dietz, Qi Zheng, Siva Sai Kumar Ratnakaram, Sean K. Whittier, David J. Varisco, Robert K. Ernst, William D. Picking, Wendy L. Picking
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-09-01
Edice:	Frontiers in Immunology
Témata:	Shigella T3SS IL-17 IFN-gamma vaccine
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1194912/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!